PART II ITEM 8 Financial Statements and Supplementary Data (In millions) Investments $ 211 Cash and cash equivalents 36 Reinsurance recoverables 448 Goodwill 168 Value of business acquired (reported in Deferred policy acquisition costs in the Consolidated Balance Sheet) 144 Other assets, including other intangibles 35 Total assets acquired 1,042 Insurance liabilities 707 Accounts payable, accrued expenses and other liabilities 9 Total liabilities acquired 716 Net assets acquired $ 326 The condensed balance sheet at the acquisition date was as follows: The results of this business have been included in the Company’s Consolidated Financial Statements from the date of acquisition. The pro forma effects on total revenues and net income assuming the acquisition had occurred as of January 1, 2011 were not material to the Company for the years ended December 31, 2012 and 2011. the District of Columbia, as well as a large, national stand-alone Medicare prescription drug business. The acquisition of HealthSpring strengthens the Company’s ability to serve individuals across their life stages as well as deepens its presence in a number of geographic markets. The addition of HealthSpring brings industry leading physician partnership capabilities and creates the opportunity to deepen the Company’s existing client and customer relationships, as well as facilitates a broader deployment of its range of health and wellness capabilities and product offerings. The Company funded the acquisition with internal cash resources. On January 31, 2012 the Company acquired the outstanding shares of HealthSpring, Inc. (‘‘HealthSpring’’) for $55 per share in cash and Cigna stock awards, representing a cost of approximately $3.8 billion. HealthSpring provides Medicare Advantage coverage in 13 states and Merger consideration:  The estimated merger consideration of $3.8 billion was determined as follows: C. Acquisition of HealthSpring, Inc. (In millions, except per share amounts) HealthSpring, Inc. common shares outstanding at January 30, 2012 67.8 Less: common shares outstanding not settled in cash (0.1) Common shares settled in cash 67.7 Price per share $ 55 Cash consideration for outstanding shares $ 3,725 Fair value of share-based compensation awards 65 Additional cash and equity consideration 21 TOTAL MERGER CONSIDERATION $ 3,811 were generally consistent with those disclosed in Note 21 to the Company’s 2012 Consolidated Financial Statements, except the expected life assumption of these options ranged from 1.8 to 4.8 years and the exercise price did not equal the market value at the grant date. Fair value of the new stock options approximated intrinsic value because the exercise price at the acquisition date for substantially all of the options was significantly below Cigna’s stock price. Fair value of share-based compensation awards. On the date of the acquisition, HealthSpring employees’ awards of options and restricted shares of HealthSpring stock were rolled over to Cigna stock options and restricted stock. Each holder of a HealthSpring stock option or restricted stock award received 1.24 Cigna stock options or restricted stock awards. The conversion ratio of 1.24 at the date of acquisition was determined by dividing the acquisition price of HealthSpring shares of $55 per share by the price of Cigna stock on January 31, 2012 of $44.43. The Cigna stock option exercise price was determined by using this same conversion ratio. Vesting periods and the remaining life of the options rolled over with the original HealthSpring awards. The fair value of these options and restricted stock awards was included in the purchase price to the extent that services had been provided prior to the acquisition based on the grant date of the original HealthSpring awards and vesting periods. The remaining fair value not included in the purchase price will be recorded as compensation expense in future periods over the remaining vesting periods. Most of the expense is expected to be recognized in 2012 and 2013. The Company valued the share-based compensation awards as of the acquisition date using Cigna’s stock price for restricted stock and a Black-Scholes pricing model for stock options. The assumptions used 78 CIGNA CORPORATION -  2012 Form  10-K